These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

695 related items for PubMed ID: 33915347

  • 1. Molecular epidemiology and antimicrobial resistance of Clostridioides difficile in Germany, 2014-2019.
    Abdrabou AMM, Ul Habib Bajwa Z, Halfmann A, Mellmann A, Nimmesgern A, Margardt L, Bischoff M, von Müller L, Gärtner B, Berger FK.
    Int J Med Microbiol; 2021 May; 311(4):151507. PubMed ID: 33915347
    [Abstract] [Full Text] [Related]

  • 2. Implementation of a Clostridioides difficile sentinel surveillance system in Germany: First insights for 2019-2021.
    Abdrabou AMM, Bischoff M, Mellmann A, von Müller L, Margardt L, Gärtner BC, Berger FK, German C. difficile surveillance group.
    Anaerobe; 2022 Oct; 77():102548. PubMed ID: 35307546
    [Abstract] [Full Text] [Related]

  • 3. Changes in Clostridium (Clostridioides) difficile PCR-Ribotype Distribution and Antimicrobial Resistance in a German Tertiary Care Hospital Over the Last 10 Years.
    Piepenbrock E, Stelzer Y, Berger F, Jazmati N.
    Curr Microbiol; 2019 Apr; 76(4):520-526. PubMed ID: 30805700
    [Abstract] [Full Text] [Related]

  • 4. Characterization of Clostridioides difficile isolates recovered from two Phase 3 surotomycin treatment trials by restriction endonuclease analysis, PCR ribotyping and antimicrobial susceptibilities.
    Cheknis A, Devaris D, Chesnel L, Dale SE, Nary J, Sambol SP, Citron DM, Goering RV, Johnson S.
    J Antimicrob Chemother; 2020 Nov 01; 75(11):3120-3125. PubMed ID: 32747931
    [Abstract] [Full Text] [Related]

  • 5. A nationwide study of molecular epidemiology and antimicrobial susceptibility of Clostridioides difficile in South Korea.
    Byun JH, Kim H, Kim JL, Kim D, Jeong SH, Shin JH, Kim YA, Shin JH, Shin KS, Uh Y.
    Anaerobe; 2019 Dec 01; 60():102106. PubMed ID: 31655214
    [Abstract] [Full Text] [Related]

  • 6. Molecular epidemiology of endemic Clostridioides difficile infection in Japan.
    Senoh M, Kato H.
    Anaerobe; 2022 Apr 01; 74():102510. PubMed ID: 34990814
    [Abstract] [Full Text] [Related]

  • 7. Changes in molecular epidemiology and antimicrobial resistance profiles of Clostridioides (Clostridium) difficile strains in the United States between 2011 and 2017.
    Tickler IA, Obradovich AE, Goering RV, Fang FC, Tenover FC, HAI Consortium.
    Anaerobe; 2019 Dec 01; 60():102050. PubMed ID: 31173889
    [Abstract] [Full Text] [Related]

  • 8. Antimicrobial resistance progression in the United Kingdom: A temporal comparison of Clostridioides difficile antimicrobial susceptibilities.
    Jon J V, Mark H W, Jane F.
    Anaerobe; 2021 Aug 01; 70():102385. PubMed ID: 34048922
    [Abstract] [Full Text] [Related]

  • 9. Reference Susceptibility Testing and Genomic Surveillance of Clostridioides difficile, United States, 2012-17.
    Gargis AS, Karlsson M, Paulick AL, Anderson KF, Adamczyk M, Vlachos N, Kent AG, McAllister G, McKay SL, Halpin AL, Albrecht V, Campbell D, Korhonen LC, Elkins CA, Rasheed JK, Guh AY, McDonald LC, Lutgring JD, Emerging Infections Program C. difficile Infection Working Group.
    Clin Infect Dis; 2023 Mar 04; 76(5):890-896. PubMed ID: 36208202
    [Abstract] [Full Text] [Related]

  • 10. Five-year Pan-European, longitudinal surveillance of Clostridium difficile ribotype prevalence and antimicrobial resistance: the extended ClosER study.
    Freeman J, Vernon J, Pilling S, Morris K, Nicolson S, Shearman S, Clark E, Palacios-Fabrega JA, Wilcox M, Pan-European Longitudinal Surveillance of Antibiotic Resistance among Prevalent Clostridium difficile Ribotypes’ Study Group.
    Eur J Clin Microbiol Infect Dis; 2020 Jan 04; 39(1):169-177. PubMed ID: 31811507
    [Abstract] [Full Text] [Related]

  • 11. Molecular characterization, toxin detection and resistance testing of human clinical Clostridium difficile isolates from Lebanon.
    Berger FK, Rasheed SS, Araj GF, Mahfouz R, Rimmani HH, Karaoui WR, Sharara AI, Dbaibo G, Becker SL, von Müller L, Bischoff M, Matar GM, Gärtner B.
    Int J Med Microbiol; 2018 Apr 04; 308(3):358-363. PubMed ID: 29478838
    [Abstract] [Full Text] [Related]

  • 12. Molecular epidemiology and antimicrobial resistance patterns of Clostridioides difficile isolates in Algerian hospitals.
    Boudjelal Y, Krutova M, Djebbar A, Sebaihia M, Bekara MEA, Rouabhia S, Couturier J, Syed-Zaidi R, Barbut F.
    J Infect Dev Ctries; 2022 Jun 30; 16(6):1055-1063. PubMed ID: 35797301
    [Abstract] [Full Text] [Related]

  • 13. In vitro activity of eravacycline against common ribotypes of Clostridioides difficile.
    Bassères E, Begum K, Lancaster C, Gonzales-Luna AJ, Carlson TJ, Miranda J, Rashid T, Alam MJ, Eyre DW, Wilcox MH, Garey KW.
    J Antimicrob Chemother; 2020 Oct 01; 75(10):2879-2884. PubMed ID: 32719870
    [Abstract] [Full Text] [Related]

  • 14. Diversity of Circulating Clostridioides difficile Ribotypes in Mexico and Susceptibility to Fidaxomicin, Vancomycin, and Metronidazole.
    Martínez-Meléndez A, Tijerina-Rodríguez L, Collins N, Baines SD, Morfin-Otero R, Camacho-Ortíz A, Villarreal-Treviño L, Garza-González E.
    Microb Drug Resist; 2021 Dec 01; 27(12):1672-1676. PubMed ID: 34037477
    [Abstract] [Full Text] [Related]

  • 15. Clostridioides difficile infections were predominantly driven by fluoroquinolone-resistant Clostridioides difficile ribotypes 176 and 001 in Slovakia in 2018-2019.
    Plankaova A, Brajerova M, Capek V, Balikova Novotna G, Kinross P, Skalova J, Soltesova A, Drevinek P, Krutova M.
    Int J Antimicrob Agents; 2023 Jul 01; 62(1):106824. PubMed ID: 37116667
    [Abstract] [Full Text] [Related]

  • 16. Quality assurance for genotyping and resistance testing of Clostridium (Clostridioides) difficile isolates - Experiences from the first inter-laboratory ring trial in four German speaking countries.
    Berger FK, Mellmann A, von Müller L, Bischoff M, Gärtner BC, German speaking C. difficile laboratory study group.
    Anaerobe; 2020 Feb 01; 61():102093. PubMed ID: 31494260
    [Abstract] [Full Text] [Related]

  • 17. Antimicrobial susceptibility of Clostridioides difficile isolated from diarrhoeal stool specimens of Canadian patients: summary of results from the Canadian Clostridioides difficile (CAN-DIFF) surveillance study from 2013 to 2017.
    Karlowsky JA, Adam HJ, Baxter MR, Dutka CW, Nichol KA, Laing NM, Golding GR, Zhanel GG.
    J Antimicrob Chemother; 2020 Jul 01; 75(7):1824-1832. PubMed ID: 32294172
    [Abstract] [Full Text] [Related]

  • 18. The ClosER study: results from a three-year pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes, 2011-2014.
    Freeman J, Vernon J, Pilling S, Morris K, Nicholson S, Shearman S, Longshaw C, Wilcox MH, Pan-European Longitudinal Surveillance of Antibiotic Resistance among Prevalent Clostridium difficile Ribotypes Study Group.
    Clin Microbiol Infect; 2018 Jul 01; 24(7):724-731. PubMed ID: 29066403
    [Abstract] [Full Text] [Related]

  • 19. Surveillance of antimicrobial susceptibilities reveals high proportions of multidrug resistance in toxigenic Clostridium difficile strains in different areas of Poland.
    Lachowicz D, Pituch H, Wultańska D, Kuijper E, Obuch-Woszczatyński P.
    Anaerobe; 2020 Apr 01; 62():102167. PubMed ID: 32109736
    [Abstract] [Full Text] [Related]

  • 20. Characterization of Healthcare-Associated and Community-Associated Clostridioides difficile Infections among Adults, Canada, 2015-2019.
    Du T, Choi KB, Silva A, Golding GR, Pelude L, Hizon R, Al-Rawahi GN, Brooks J, Chow B, Collet JC, Comeau JL, Davis I, Evans GA, Frenette C, Han G, Johnstone J, Kibsey P, Katz KC, Langley JM, Lee BE, Longtin Y, Mertz D, Minion J, Science M, Srigley JA, Stagg P, Suh KN, Thampi N, Wong A, Hota SS.
    Emerg Infect Dis; 2022 Jun 01; 28(6):1128-1136. PubMed ID: 35470794
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.